Year Established: 1989
Pharma Revenues: $15,634 (+3%)
Net Income: $3,046 (+28%)
R&D: $3,038 (-16%)
TOP SELLING DRUGS
|Jardiance||type 2 diabetes||$2,409||40%|
|Trajenta||type 2 diabetes||$1,745||6%|
|Ofev||idiopathic pulmonary fibrosis||$1,669||28%|
|Activase||myocardial infarction, acute, Pulmonary embolism, stroke||$502||11%|
During the year, Boehringer Ingelheim strengthened its cancer immunology portfolio when it paid $366 million to acquire AMAL Therapeutics and its novel cancer vaccines platform. The Swiss biotech is focused on cancer immunotherapy and advancing first-in-class therapeutic cancer vaccines derived from its technology platform KISIMA. AMAL’s lead vaccine ATP128 is currently developed for stage IV colorectal cancer and recently began first-in-human trials. Boehringer plans to develop new therapies by combining assets from its cancer immunology portfolio with AMAL’s KISIMA immunization platform.
In positive pipeline news, Boehringer received approval from the U.S. FDA for Ofev (nintedanib) as the first and only medicine to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease.
Expanding its global reach and footprint in China, Boehringer initiated a capacity expansion at its commercial manufacturing site for biologics in China. The expansion covers an additional bioreactor and includes utilities and infrastructure to support GMP operations of 2x 2.000L single use bioreactor manufacturing lines.
Through its biopharmaceutical contract manufacturing business, the company began manufacturing the commercial supply of a monoclonal antibody out of its China manufacturing OASIS facility in 2019. This will be the first commercial drug manufactured in the Shanghai facility. Following the commercial manufacturing of a client’s antibody, a number of investigational drugs are in Boehringer’s contract manufacturing business pipeline for potential future market launch and commercial supply out of Shanghai.
On the research front, Boehringer entered several collaborations during the year to advance it pipeline. With the University of Texas MD Anderson Cancer Center it set up a new multi-year partnership to conduct collaborative research to advance therapies for various types of cancers, including gastrointestinal and lung cancers. The deal includes the establishment of a joint Virtual Research and Development Center, designed to enable effective data sharing and analysis between the organizations. New potential gastrointestinal and lung cancer therapies from Boehringer’s pipeline will be combined with MD’s drug development capabilities.
A collaboration and license agreement with Yuhan Corp. aims to develop a first-in-class dual agonist for the treatment of nonalcoholic steatohepatitis (NASH) and related liver diseases that combines GLP-1 and FGF21 activity in one molecule. Yuhan will provide its expertise in FGF21 biology, obesity and NASH.
With Bridge Biotherapeutics, Boehringer formed a new collaboration and license agreement with the goal of developing Bridge’s autotaxin inhibitor, BBT-877, for patients with fibrosing interstitial lung diseases, including Idiopathic Pulmonary Fibrosis (IPF).
Lastly, Boehringer Ingelheim and Inflammasome Therapeutics inked a co-development and license agreement to develop up to three therapies for patients with retinal diseases. By combining Inflammasome’s unique intravitreal (IVT) drug delivery technologies with Boehringer Ingelheim’s compounds from its retinal disease pipeline portfolio, Boehringer aims to develop novel therapies for retinal diseases.